Month: February 2022

Senseonics Announces FDA Approval of the Eversense® E3 Continuous Glucose Monitoring System for Use for Up to 6 months; Provides 2022 Business Outlook

The world’s first and only long-term implantable CGM system now offers patients exceptional accuracy for 6 months GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics...

NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR(TM) in Head and Neck Squamous Cell Carcinoma

RaDaR demonstrated 100% specificity in patients with no recurrence and 100% sensitivity in patients with clinical recurrenceFT MYERS, FL /...

error: Content is protected !!